Patents by Inventor Fumio Samizo
Fumio Samizo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8242084Abstract: The present invention provides a novel tumor antigen peptide and its cancer vaccine, specifically, a peptide dimer wherein two peptide monomers consisting of 7-30 amino acids including at least one cysteine residue and being capable of producing a tumor antigen peptide are bound each other through a disulfide bond.Type: GrantFiled: June 7, 2010Date of Patent: August 14, 2012Assignees: Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co., Ltd., International Institute of Cancer Immunology, Inc.Inventors: Haruo Sugiyama, Hideo Takasu, Fumio Samizo
-
Patent number: 7879843Abstract: A medicine which contains as an active ingredient a benzothiazin-3-one-compound represented by the formula (1): (wherein n is 3 or 4; R represents ethyl or hydrogen; and R1 represents hologeno, alkoxy, haloalkyl, or haloalkoxy) or a pharmaceutically acceptable salt thereof. It is useful as a therapeutic or preventive agent for arthrosis deformans, chondrodegenerative discases such as chronic articular rheumatism, cancers, gingivitis, etc. Also provided are an intermediate for the compound and a process for producing the compound.Type: GrantFiled: August 26, 2009Date of Patent: February 1, 2011Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Fumio Samizo, Yoshihiro Horiuchi, Nobuhisa Fukuda, Katsunori Tsuboi, Atsushi Makita
-
Publication number: 20100292164Abstract: The present invention provides a novel tumor antigen peptide and its cancer vaccine, specifically, a peptide dimer wherein two peptide monomers consisting of 7-30 amino acids including at least one cysteine residue and being capable of producing a tumor antigen peptide are bound each other through a disulfide bond.Type: ApplicationFiled: June 7, 2010Publication date: November 18, 2010Applicant: HARUO SUGIYAMAInventors: Haruo SUGIYAMA, Hideo Takasu, Fumio Samizo
-
Publication number: 20100009976Abstract: A medicine which contains as an active ingredient a benzothiazin-3-one-compound represented by the formula (1): (wherein n is 3 or 4; R represents ethyl or hydrogen; and R1 represents hologeno, alkoxy, haloalkyl, or haloalkoxy) or a pharmaceutically acceptable salt thereof. It is useful as a therapeutic or preventive agent for arthrosis deformans, chondrodegenerative discases such as chronic articular rheumatism, cancers, gingivitis, etc. Also provided are an intermediate for the compound and a process for producing the compound.Type: ApplicationFiled: August 26, 2009Publication date: January 14, 2010Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.Inventors: Fumio Samizo, Yoshihiro HORIUCHI, Nobuhisa Fukuda, Katsunori Tsuboi, Atsushi Makita
-
Patent number: 7598240Abstract: A medicine which contains as an active ingredient a benzothiazin-3-one-compound represented by the formula (1): (wherein n is 3 or 4; R represents ethyl or hydrogen; and R1 represents hologeno, alkoxy, haloalkyl, or haloalkoxy) or a pharmaceutically acceptable salt thereof. It is useful as a therapeutic or preventive agent for arthrosis deformans, chondrodegenerative discases such as chronic articular rheumatism, cancers, gingivitis, etc. Also provided are an intermediate for the compound and a process for producing the compound.Type: GrantFiled: February 28, 2005Date of Patent: October 6, 2009Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Fumio Samizo, Yoshihiro Horiuchi, Nobuhisa Fukuda, Katsunori Tsuboi, Atsushi Makita
-
Patent number: 7378384Abstract: Novel substituted type peptides of WT1 wherein the cysteine residue is substituted with a defined amino acid residue, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. Peptides which comprise an amino acid sequence of the formula: X-Y-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 4) wherein X represents Ser, Ala, Abu, Arg, Lys, Orn, Cit, Leu, Phe, or Asn, and Y represents Tyr or Met, and which has an activity to induce CTLs, polynucleotides encoding said peptides, cancer vaccines which comprise those peptides or polynucleotides as an active ingredient, and the like are disclosed.Type: GrantFiled: September 19, 2003Date of Patent: May 27, 2008Assignees: International Institute of Cancer Immunology, Inc., Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co., Ltd.Inventors: Haruo Sugiyama, Masashi Gotoh, Hideo Takasu, Fumio Samizo, Naoto Kusunose, Masashi Nakatsuka
-
Publication number: 20080058321Abstract: A medicine which contains as an active ingredient a benzothiazin-3-one-compound represented by the formula (1): (wherein n is 3 or 4; R represents ethyl or hydrogen; and R1 represents hologeno, alkoxy, haloalkyl, or haloalkoxy) or a pharmaceutically acceptable salt thereof. It is useful as a therapeutic or preventive agent for arthrosis deformans, chondrodegenerative discases such as chronic articular rheumatism, cancers, gingivitis, etc. Also provided are an intermediate for the compound and a process for producing the compound.Type: ApplicationFiled: February 28, 2005Publication date: March 6, 2008Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.Inventors: Fumio Samizo, Yoshihiro Horiuchi, Nobuhisa Fukuda, Katsunori Tsuboi, Atsushi Makita
-
Publication number: 20060217297Abstract: The present invention provides a novel tumor antigen peptide and its cancer vaccine, specifically, a peptide dimer wherein two peptide monomers consisting of 7-30 amino acids including at least one cysteine residue and being capable of producing a tumor antigen peptide are bound each other through a disulfide bond.Type: ApplicationFiled: January 15, 2004Publication date: September 28, 2006Inventors: Haruo Sugiyama, Hideo Takasu, Fumio Samizo
-
Publication number: 20060205667Abstract: Novel substituted type peptides of WT1 wherein the cysteine residue is substituted with a defined amino acid residue, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. Peptides which comprise an amino acid sequence of the formula: X—Y-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 4) wherein X represents Ser, Ala, Abu, Arg, Lys, Orn, Cit, Leu, Phe, or Asn, and Y represents Tyr or Met, and which has an activity to induce CTLs, polynucleotides encoding said peptides, cancer vaccines which comprise those peptides or polynucleotides as an active ingredient, and the like are disclosed.Type: ApplicationFiled: September 19, 2003Publication date: September 14, 2006Inventors: Haruo Sugiyama, Masashi Gotoh, Hideo Takasu, Fumio Samizo, Naoto Kusunose, Masashi Nakatsuka
-
Patent number: 6713477Abstract: A hydroxamic acid derivative represented by formula (1) or a prodrug thereof, or a pharmaceutically acceptable salt thereof, which has a matrix metalo-proteinase inhibitor.Type: GrantFiled: November 9, 2001Date of Patent: March 30, 2004Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Gerard Robert Scarlato, Sara Sabina Hadida Ruah, Tamiki Nishimura, Masashi Nakatsuka, Fumio Samizo, Yumiko Kamikawa, Hitoshi Houtigai
-
Patent number: 5234691Abstract: A preparation obtained by coating granules containing both a basic medical agent hydrochloride (e.g. allotinolol hydrochloride) and a polyanion the particles of which are present in the form of a discontinuous layer, with a film containing a slightly water-soluble substance, can release said agent at a controlled rate without influenced by the physiological factors of the gastrointestinal tract of a patient when orally administered.Type: GrantFiled: October 26, 1990Date of Patent: August 10, 1993Assignee: Sumitomo Pharmaceuticals Co., Ltd.Inventors: Akira Uemura, Fumio Samizo, Tetsuo Noguchi